{"title":"谵妄是辉瑞公司和BioNTech公司BNT162b2 mRNA疫苗的不良反应","authors":"Lilia M. Sierra Galan, Raquel Cohen Shaooli","doi":"10.4103/ajim.ajim_66_21","DOIUrl":null,"url":null,"abstract":"Abstract The spike-protein severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine has developed different adverse reactions. Still, delirium has not been reported in a low-risk patient, and it is important to consider it and recognize it as a possibility in all severity risk patients. We present a 76-year-old male patient who developed delirium after receiving the second dose of the BNT162b2 mRNA vaccine from Pfizer Inc. and BioNTech®. We theorize about the potential pathophysiology mechanisms involved.","PeriodicalId":8012,"journal":{"name":"APIK Journal of Internal Medicine","volume":"12 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Delirium as an Adverse Reaction to BNT162b2 mRNA Vaccine from Pfizer Inc., and BioNTech\",\"authors\":\"Lilia M. Sierra Galan, Raquel Cohen Shaooli\",\"doi\":\"10.4103/ajim.ajim_66_21\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract The spike-protein severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine has developed different adverse reactions. Still, delirium has not been reported in a low-risk patient, and it is important to consider it and recognize it as a possibility in all severity risk patients. We present a 76-year-old male patient who developed delirium after receiving the second dose of the BNT162b2 mRNA vaccine from Pfizer Inc. and BioNTech®. We theorize about the potential pathophysiology mechanisms involved.\",\"PeriodicalId\":8012,\"journal\":{\"name\":\"APIK Journal of Internal Medicine\",\"volume\":\"12 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"APIK Journal of Internal Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/ajim.ajim_66_21\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"APIK Journal of Internal Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ajim.ajim_66_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Delirium as an Adverse Reaction to BNT162b2 mRNA Vaccine from Pfizer Inc., and BioNTech
Abstract The spike-protein severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine has developed different adverse reactions. Still, delirium has not been reported in a low-risk patient, and it is important to consider it and recognize it as a possibility in all severity risk patients. We present a 76-year-old male patient who developed delirium after receiving the second dose of the BNT162b2 mRNA vaccine from Pfizer Inc. and BioNTech®. We theorize about the potential pathophysiology mechanisms involved.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
